Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribavirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.90 |
| ▸ | TSHR | P16473 | 2/20 | 0.90 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.90 |
| ▸ | THPO | P40225 | 2/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.90 |
| ▸ | GLA | P06280 | 1/20 | 0.90 |
| ▸ | EIF4E | P06730 | 1/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.90 |
| ▸ | TOP1 | P11387 | 1/20 | 0.90 |
| ▸ | PNP | P00491 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribavirin SCHEMBL1200226 | 1.00 | LMNA (0.90) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL5473652 | 0.99 | LMNA (0.88) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL18537396 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL14379766 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL2631654 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL3954927 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL12758160 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL20806078 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL21311208 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL41472 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120060190-A | Drug target of plant bunyavirus and RNA replicase protein and application thereof | 南京农业大学 | 2025-05-30 | — | — | CN | claimed |
| WO-2009043096-A1 | IMPROVED METHOD FOR MUTAGENESIS | ARANA THERAPEUTICS (VIC) PTY LTD (AU) | 2009-04-09 | — | — | WO | claimed |
| CN-120060190-A | Drug target of plant bunyavirus and RNA replicase protein and application thereof | 南京农业大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-120051271-A | Methods for treating infectious diseases | 欣扬生医股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4522128-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | Suntec Medical, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073163-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | SUNTEC MEDICAL INC (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2023220086-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | SUNTEC MEDICAL, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230242901-A1 | SYSTEM FOR SCREENING THERAPEUTIC AGENTS FOR CORONAVIRUS INFECTION | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2023-08-03 | — | — | US | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| EP-4095247-A1 | SCREENING SYSTEM FOR THERAPEUTIC AGENT FOR CORONAVIRUS INFECTION | Korea Institute of Oriental Medicine (KR) | 2022-11-30 | — | — | EP | disclosed |
| WO-2004062676-A1 | -MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-29 | — | — | WO | disclosed |
| US-20040034206-A1 | Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors | SCHERING CORPORATION | 2004-02-19 | — | — | US | disclosed |
| WO-2003101199-A1 | COMBINATION THERAPY FOR RNA VIRUS INFECTIONS INVOLVING RIBAVIRIN AND IMPDH INHIBITORS | SCHERING CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003099229-A2 | FUNCTIONAL PROTEIN EXPRESSION FOR RAPID CELL-FREE PHENOTYPING | FOCUS TECHNOLOGIES, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1278837-A2 | INTERNAL DE NOVO INITIATION SITES OF THE HCV NS5B POLYMERASE AND USE THEREOF | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-01-29 | — | — | EP | disclosed |
| US-20020061290-A1 | Methods of preventing or treating West Nile virus and other infection | NEW YORK HOSPITAL MEDICAL CENTER OF QUEENS, THE | 2002-05-23 | — | — | US | disclosed |
| WO-2002015664-A2 | METHODS OF PREVENTING OR TREATING WEST NILE VIRUS AND OTHER INFECTIONS | THE NEW YORK HOSPITAL MEDICAL CENTER OF QUEENS (US) | 2002-02-28 | — | — | WO | disclosed |
| US-20010055756-A1 | Internal de novo initiation sites of the HCV NS5B polymerase and use thereof | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-27 | — | — | US | disclosed |
| WO-2001083736-A2 | INTERNAL DE NOVO INITIATION SITES OF THE HCV NS5B POLYMERASE AND USE THEREOF | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034206-A1 | Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors | IFNAR1, EIF2AK2, IMPDH1 | LMNA 1402/4885SMN1; SMN2 1598/4885ALDH1A1 133/4885 |
| US-20250073163-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | CD14, PML, SARS1 | LMNA 437/4885SMN1; SMN2 594/4885ALDH1A1 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.